In 1973, a previously healthy 4-year-old U.S. military-dependent boy presented to a local clinic in Okinawa for evaluation ...

Jennifer L. Hsiao, MD, is associate professor of dermatology at Keck School of Medicine at University of Southern ...

The FDA has approved technosphere insulin, an inhaled form of human insulin, for children and adolescents aged 6 years and ...

The End-Stage Renal Disease Treatment Choices model did not lead to significant improvements in home dialysis or kidney transplant rates but did lead to an increase in financial penalties, according ...

Please provide your email address to receive an email when new articles are posted on . Females achieved procedural benefits at a faster rate than males after arthroscopic femoroacetabular impingement ...

Please provide your email address to receive an email when new articles are posted on . Dawn Marie R. Davis, MD, is professor of dermatology and pediatrics at Mayo Clinic in Rochester, Minnesota.

Suneel Kamath, MD, a gastrointestinal medical oncologist at Cleveland Clinic, spoke with Healio about a research letter that showed colorectal cancer is the leading cause of cancer death in adults ...

Please provide your email address to receive an email when new articles are posted on . Clinicians should carefully monitor patients with inflammatory bowel disease and comorbid Clostridioides ...

In this video, Suneel Kamath, MD, discussed the approval of encorafenib (Braftovi, Array BioPharma) in combination with cetuximab (Erbitux, ImClone) and fluorouracil-based chemotherapy in metastatic ...

Please provide your email address to receive an email when new articles are posted on . King pioneered the use of JAK inhibitors in dermatology, and his work revealed the broad utility of JAK ...

Please provide your email address to receive an email when new articles are posted on . Laser treatments, anti-VEGF injections and surgery can all be used to treat diabetic retinopathy. David Baxley, ...

Women accounted for less than 30% of first and senior authors of phase 3 solid-tumor trials presented at ASCO Annual Meeting between 2015 and 2025.Trends improved throughout the decade, according to ...